Here's Why You Should Hold DaVita Stock in Your Portfolio for Now

DaVita reported mixed Q3 2025 results with sequential growth in U.S. dialysis treatments and revenue per treatment but a year‑over‑year decline in the bottom line; it served ~293,200 patients at 3,247 outpatient centers (2,662 U.S., 585 international), opened three U.S. centers and acquired 58 centers outside the U.S. in Q3. Management projects 12.6% growth over the next five years, the Zacks 2025 EPS consensus is stable at $10.70, Q4 revenue consensus is $3.53 billion (+6.9% YoY) while Q4 EPS consensus of $3.24 implies a 44.6% YoY decline; material downside risks include dependence on commercial payers and potential margin pressure from shifts toward government reimbursement.

Analysis

Market structure: DVA’s -24.9% YTD underperformance versus industry +11.2% and S&P +12.9% signals a re‑pricing of dialysis asset exposure tied to commercial payers. Winners include Medicare Advantage insurers (MA = pricing advantage), home‑dialysis suppliers and diagnostics/medtech peers (IDXX, BSX, STE) that capture non‑facility revenue; losers are in‑center dependent operators (DVA, FMS‑peer risk) facing margin compression as MA/Medicaid share rises. Cross‑asset: expect widening credit spreads and higher equity implied vol for DVA, modest upside for payer equity and medtech FX sensitivity as international revenue share grows (585 centers outside US).

Risk assessment: Tail risks include adverse CMS/MA reimbursement changes or a rapid commercial→government shift (e.g., MA penetration +3–5pp in 12 months) that could force 5–15% closure of unprofitable centers and steep margin loss. Timeline: immediate (days) = earnings/guidance volatility; short (weeks–months) = MA enrollment data, CMS notices and Q4 results; long (quarters–years) = success of international tuck‑ins and home‑dialysis adoption. Hidden dependencies: JV minority partners, concentration of commercial contracts, and supply agreements (dialyzers/pharma) that can transmit margin shocks.

Trade implications: Direct: asymmetric short DVA via defined‑risk put spreads (3–6 month) and long IDXX/BSX/STE equities or calls to capture secular medtech strength; pair: long IDXX (or BSX) vs short DVA to exploit relative fundamentals. Options: buy 3–6 month DVA puts 15–25% OTM or sell iron‑condor wings to monetize higher IV with limited risk; consider payer longs (UNH, CVS) for MA tailwind. Entry: scale into positions on post‑earnings fades or if DVA rallies back toward 10–15% above current level; exits tied to confirmed MA reimbursement relief or 12–18 month execution milestones on international growth.

Contrarian angles: Consensus fixates on commercial‑payer deterioration; market may be underpricing international M&A (58 centers acquired Q3 outside US) and value‑based care upside if CMMI contracts reduce future cost of care. Reaction may be overdone if DVA stabilizes normalized non‑acquired treatments and converts JV economics — there’s precedent of post‑restructuring rebounds in dialysis names. Unintended consequence: aggressive shorting could force bargain M&A or asset sales that realize value; conversely, faster home‑therapy adoption benefits medtech winners more than investors expect.

Key Decisions for Investors

• Establish a defined‑risk short position in DVA equal to 2–3% portfolio notional: buy a 3–6 month put spread 15–25% OTM (long put, finance with a lower strike short put) to target 25–40% downside while capping max loss to ~2–3% of portfolio; trim on a 15% adverse move.
• Establish a 2–3% long in IDXX via shares or 6–9 month 25% OTM call options (rollable) to capture durable diagnostic/recurring revenue growth; set a 12‑month target of +20–30% and a protective stop at -12%.
• Implement a pair trade: long BSX (1.5% portfolio) and short DVA (1.5%) to exploit medtech secular strength vs dialysis payer exposure; rebalance if spread narrows >20% or after two consecutive quarters of DVA margin stabilization.
• Monitor CMS ESRD payment notices and monthly MA enrollment prints over the next 30–90 days; if MA share increases >3 percentage points YoY or CMS issues negative ESRD payment guidance, add to DVA short exposure and consider buying protection on DVA corporate bonds (2–5% notional).